Archives

  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-04
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • 2021-12
  • 2021-11
  • 2021-10
  • 2021-09
  • 2021-08
  • 2021-07
  • 2021-06
  • 2021-05
  • 2021-04
  • 2021-03
  • 2021-02
  • 2021-01
  • 2020-12
  • 2020-11
  • 2020-10
  • 2020-09
  • 2020-08
  • 2020-07
  • 2020-06
  • 2020-05
  • 2020-04
  • 2020-03
  • 2020-02
  • 2020-01
  • 2019-12
  • 2019-11
  • 2019-10
  • 2019-09
  • 2019-08
  • 2019-07
  • 2019-06
  • 2019-05
  • 2019-04
  • 2018-07

    • Cisplatin: Unraveling Novel Pyroptosis Pathways in Cancer...

    2026-01-19

    Cisplatin: Unraveling Novel Pyroptosis Pathways in Cancer Research

    Introduction

    Cisplatin (CDDP) has long been recognized as a gold-standard DNA crosslinking agent for cancer research, renowned for its robust capacity to induce apoptosis and inhibit tumor growth. However, recent advances illuminate a new dimension of Cisplatin’s action—its ability to trigger pyroptosis, a distinct form of programmed cell death. This article provides a comprehensive, technically rigorous exploration of Cisplatin’s multifaceted mechanisms, with a special focus on GSDME-mediated pyroptosis, setting the stage for innovative research directions far beyond traditional apoptosis assays.

    Cisplatin: Structure, Physicochemical Profile, and Handling

    Cisplatin (CAS 15663-27-1), chemically designated as Cl2H6N2Pt, is a platinum-based chemotherapeutic compound with a molecular weight of 300.05. Its cytotoxic efficacy arises from its unique ability to form both intra- and inter-strand DNA crosslinks at guanine-rich sites, thereby disrupting essential processes such as DNA replication and transcription. Notably, Cisplatin is insoluble in ethanol and water, but dissolves in DMF at concentrations ≥12.5 mg/mL. For optimal stability, it should be stored as a powder in the dark at room temperature; freshly prepared DMF solutions are recommended for experimental use, as DMSO can inactivate the compound.

    The Cisplatin (SKU A8321) by APExBIO is widely adopted in cancer research, particularly in studies on chemotherapy resistance, DNA damage response, and diverse apoptosis mechanisms in in vitro and in vivo models. Experimental protocols suggest warming and ultrasonic treatment to enhance solubility, especially for high-throughput or quantitative apoptosis assays.

    Mechanisms of Action: From DNA Crosslinking to Programmed Cell Death

    Classical Pathways: DNA Crosslinking and p53-Mediated Apoptosis

    Cisplatin’s primary mode of action involves covalent binding to DNA, creating crosslinks that distort the double helix and stall essential cellular processes. This DNA damage activates the p53 tumor suppressor, initiating a cascade that results in caspase-dependent apoptosis—particularly involving caspase-3 and caspase-9. Concurrently, Cisplatin induces oxidative stress, elevating reactive oxygen species (ROS), which further undermine cellular integrity via lipid peroxidation and ERK-dependent apoptotic signaling. These pathways are foundational for its application in apoptosis assays and tumor growth inhibition in xenograft models.

    Emerging Insights: GSDME-Mediated Pyroptosis

    While apoptosis has been extensively characterized in the context of Cisplatin treatment, recent research has uncovered its capacity to induce pyroptosis, a highly inflammatory, caspase-dependent form of cell death. A pivotal study (Cai et al., 2023) demonstrated that Cisplatin activates the gasdermin E (GSDME) protein in gastric cancer cells. Upon activation, GSDME undergoes cleavage, leading to cell membrane rupture and subsequent pyroptosis. Notably, silencing GSDME via siRNA markedly increased the survival rate of Cisplatin-treated gastric cancer cells, underscoring GSDME’s critical role as both a mediator of cell death and a prognostic marker.

    This mechanism not only provides a novel avenue for overcoming chemotherapy resistance but also expands the experimental utility of Cisplatin beyond conventional apoptosis assays, enabling detailed interrogation of both apoptotic and pyroptotic cell death in cancer models.

    Comparative Perspective: Differentiating Apoptosis and Pyroptosis

    Most existing literature and application guides—such as the workflow optimization-focused "Cisplatin: Gold-Standard DNA Crosslinking Agent for Cancer Research"—emphasize Cisplatin’s role in apoptosis induction and DNA crosslinking. While these resources provide valuable troubleshooting and workflow insights, they seldom dissect the distinct morphological and molecular hallmarks that differentiate apoptosis from pyroptosis. Apoptosis is characterized by cell shrinkage, DNA fragmentation, and formation of apoptotic bodies, typically without eliciting an inflammatory response. In contrast, pyroptosis involves cell swelling, membrane pore formation, and the release of pro-inflammatory intracellular contents, often amplifying anti-tumor immunity.

    By elucidating the GSDME-dependent pyroptotic pathway, this article provides a fresh perspective, enabling researchers to design experiments that simultaneously monitor both apoptotic and pyroptotic endpoints, thus enhancing the granularity and translational relevance of their cancer research models.

    Advanced Applications: Pyroptosis as a Target in Chemotherapy Resistance Studies

    Addressing Chemoresistance in Gastric Cancer

    Gastric cancer remains among the most lethal malignancies worldwide, with high rates of chemoresistance and recurrence. The referenced study by Cai et al. provides compelling evidence that GSDME expression is a poor prognostic factor; its upregulation following Cisplatin treatment correlates with increased pyroptosis and reduced tumor cell survival. Importantly, GSDME was identified as an independent prognostic marker for overall survival in gastric cancer patients. These insights suggest that combining Cisplatin-based chemotherapy with strategies to enhance GSDME expression or activity could sensitize resistant tumors, opening new frontiers in chemotherapy resistance studies.

    In Vivo Models: Tumor Growth Inhibition via Pyroptosis

    Traditional in vivo studies often focus on apoptosis and tumor volume reduction as endpoints. However, integrating pyroptosis readouts—such as GSDME cleavage and inflammatory cytokine release—provides a more comprehensive assessment of tumor growth inhibition in xenograft models. Recent protocols recommend intravenous administration of Cisplatin at 5 mg/kg on days 0 and 7 to achieve significant tumor suppression, with subsequent analysis of both apoptotic and pyroptotic cell death markers.

    Expanding the Toolbox: Multiplex Assays for Apoptosis and Pyroptosis

    To realize the full potential of Cisplatin as a research tool, advanced multiplex assays can simultaneously quantify caspase-3/9 activation, GSDME cleavage, DNA damage, and ROS generation. This multidimensional approach offers a nuanced understanding of both caspase-dependent apoptosis and GSDME-driven pyroptosis, facilitating drug screening and mechanistic studies in diverse cancer models, including ovarian and head and neck squamous cell carcinoma.

    Operational Best Practices: Maximizing Reproducibility and Data Quality

    Achieving consistent, high-fidelity results with Cisplatin (or its variants sometimes misspelled as "cysplatin" or "cisplastin") relies on meticulous handling. The "Scenario-Driven Solutions" article offers workflow advice for apoptosis and cell viability assays, while the present article extends these recommendations to pyroptosis and advanced chemoresistance studies. For best results:

    • Prepare solutions fresh in DMF; avoid DMSO for reconstitution.
    • Use gentle warming and ultrasonication to facilitate dissolution without degrading bioactivity.
    • Store powder in the dark at room temperature and protect solutions from prolonged light exposure.
    • Incorporate multiplex endpoint assays—such as apoptosis and pyroptosis markers—for a more holistic evaluation.

    These operational refinements are essential for maintaining experimental reproducibility, especially in studies dissecting complex cell death phenotypes.

    Content Differentiation: Beyond Conventional Mechanisms

    While most available articles—such as "Cisplatin: Benchmark DNA Crosslinking Agent for Cancer Research"—focus on workflow optimization, apoptosis assays, and resistance mechanisms, this cornerstone article uniquely highlights the emerging role of pyroptosis in Cisplatin-mediated cytotoxicity. By integrating the latest findings on GSDME activation and its implications for chemoresistance, we provide a deeper, more nuanced understanding of Cisplatin’s utility in cancer biology. Researchers are thus empowered to not only optimize their workflows but also to pioneer studies at the forefront of cell death research.

    Conclusion and Future Outlook

    Cisplatin (CDDP) remains an indispensable DNA crosslinking agent for cancer research, but its capabilities extend beyond classical apoptosis induction. The recent identification of GSDME-mediated pyroptosis as a parallel and potent cell death pathway opens transformative avenues for basic and translational oncology. By leveraging APExBIO’s rigorously formulated Cisplatin (SKU A8321), researchers can advance beyond traditional endpoints, exploring both apoptotic and pyroptotic mechanisms to unravel the complexities of chemoresistance and tumor suppression. As multiplex assays and in vivo models continue to evolve, the dual targeting of apoptosis and pyroptosis promises to redefine the landscape of cancer therapeutics and experimental design.

    References: